Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
about
NDST1 Preferred Promoter Confirmation and Identification of Corresponding Transcriptional Inhibitors as Substrate Reduction Agents for Multiple Mucopolysaccharidosis DisordersSphingolipids and phospholipids in insulin resistance and related metabolic disorders.Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Substrate reduction therapy for Krabbe's disease.Pharmacotherapy of Gaucher Disease: Current and Future Options.
P2860
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@ast
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@en
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@nl
type
label
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@ast
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@en
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@nl
prefLabel
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@ast
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@en
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@nl
P2860
P921
P3181
P356
P1476
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
@en
P2093
Kelsey Turcotte
Lunawati L Bennett
P2860
P304
P3181
P356
10.2147/DDDT.S77760
P407
P5008
P577
2015-08-18T00:00:00Z